Traws Pharma grants options and RSUs to five executives with $2.33 exercise price

Traws Pharma, Inc.

Compensation Committee approved equity grants to CEO, CFO, CSO, CMO, and COO on December 12, 2025.
CEO Iain Dukes receives 147,771 options + 36,943 RSUs; CFO Charles Parker receives 61,571 options + 15,393 RSUs.
CSO C. David Pauza receives 73,886 options + 18,471 RSUs; CMO Robert Redfield receives 65,676 options + 16,419 RSUs.
COO Nikolay Savchuk receives 65,676 options + 16,419 RSUs; all options have $2.33 strike, 10-year term, vest in 1 year.
Grants made under the Amended and Restated 2021 Incentive Compensation Plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.